On January 2, 2013, Zacks Investment Research upgraded
Ironwood Pharmaceuticals, Inc.'s
) to a Zacks #1 Rank (Strong Buy).
Why the Upgrade?
Ironwood Pharma has been buoyed by a string of good news
lately. On December 17, 2012, Ironwood Pharma and partner
Forest Laboratories, Inc.
) announced the US launch of their drug Linzess (linaclotide).
The launch followed the approval of the drug by the US Food and
Drug Administration (FDA) in August 2012 for the treatment
(once-daily) of adults suffering from irritable bowel syndrome
with constipation (IBS-C) or chronic idiopathic constipation
In the EU, approval came in November 2012 under the trade name
Constella. Ironwood Pharma is collaborating with Almirall, S.A.
in EU for the drug. Ironwood Pharma is also working with its
Japanese partner, Astellas Pharma Inc. for the development of
linaclotide in Japan and other Asian countries.
Furthermore, Ironwood Pharma performed impressively in the
third quarter 2012. On October 16, Ironwood Pharma reported third
quarter earnings of 42 cents, which compared favorably with the
year-ago loss of 21 cents per share and the Zacks Consensus
Estimate of 15 cents.
All the positive factors mentioned above have contributed to
the Zacks Consensus Estimate being narrowed to a loss of 81 cents
from a loss of $1.21 over the last 90 days. For 2013, the Zacks
Consensus Estimate has been revised to a loss of $2.22 per share
from a loss of $2.38 over the same time period.
Other Stocks to Consider
The following pharma companies with favorable Zacks Rank are
also performing well and are worth considering.
Valeant Pharmaceuticals International, Inc.
) carries a Zacks #1 Rank (Strong Buy)
) holds a Zacks #2 Rank (Buy)
FOREST LABS A (FRX): Free Stock Analysis
IRONWOOD PHARMA (IRWD): Free Stock Analysis
NOVO-NORDISK AS (NVO): Free Stock Analysis
VALEANT PHARMA (VRX): Free Stock Analysis
To read this article on Zacks.com click here.